Nav: Home

Texas A&M-led collaborative study takes aim at non-alcoholic fatty liver disease

February 26, 2018

COLLEGE STATION - Texas A&M University System researchers in collaboration with the Department of Veterans Affairs and Baylor Scott & White Research Institute have completed a study identifying one of the mechanisms leading to the development of non-alcoholic fatty liver disease, or NAFLD, providing new possibilities for prevention and treatment of the disease.

The study, which included input from researchers affiliated with Wuhan University, Huazhong University of Science and Technology, Chongqing Medical University, Peking University, Augusta University and the Central Texas Veterans Health Care System was published in the journal Hepatology. It can currently be found online at

Dr. Chaodong Wu. (Texas A&M AgriLife Research photo)

"Our research involved the adenosine 2A receptor, which plays a protective role against tissue damage," said Dr. Chaodong Wu, a Texas A&M AgriLife Research scientist in the nutrition and food science department of Texas A&M University in College Station. "It can reduce overactive immune cell activity, protecting tissues from being damaged by inflammation. However, until now its role in protecting from tissue damage relative to non-alcoholic fatty liver disease was largely unknown."

Wu said through this study, the researchers examined the effects disrupting this receptor would have on aspects of obesity-associated NAFLD so they could understand the underlying mechanisms.

"While these receptors normally serve as a protective mechanism, they may be destructive if they become disrupted," he said. "For our study we used receptor-disrupted animal models for comparison to a control."

Both animal model groups were fed a high-fat diet to induce NAFLD, then were examined for inflammatory and metabolic responses.

Dr. Gianfranco Alpini. (Photo courtesy Texas A&M College of Medicine)

"The results showed those models with the disrupted receptor had an increased severity of fatty liver disease and inflammation compared to the control model fed the same high-fat diet," said Dr. Gianfranco Alpini, distinguished professor in the medical physiology department at Texas A&M College of Medicine. Alpini is also a senior research scientist at Central Texas Veterans Health Care System and director of the Baylor Scott & White Digestive Disease Research Center.

Alpini said the study's investigation of the macrophages--large white blood cells that ingest foreign particles and infectious microorganisms--and liver cells of the receptor-disrupted animal models showed increased pro-inflammatory responses and enhanced fat deposition.

"Receptor deficiency also significantly increased the amount of a regulatory element-binding protein in the liver cells of fasted animal models," said Dr. Heather Francis, associate professor of medical physiology at Texas A&M College of Medicine and the study's co-author. "The increase in this protein was commensurate with an associated increase in the potential for fatty deposits in the liver."

Wu said the accumulative study results demonstrated receptor disruption in both macrophages and liver cells accounts for increased severity of NAFLD, likely through increasing inflammation and elevating fat deposits by stimulating the activity of a factor controlling protein expression of fat deposition.

"Overall, the study validates the importance of adenosine 2A receptor as a therapeutic and/or preventive target for NAFLD," Wu said. "This is significant in that it demonstrates the feasibility of targeting that receptor to treat non-alcoholic fatty liver disease by means of its activation."

He said based on the results generated, once bioactive food components capable of activating the receptor can be identified, these components and foods enriched with these components can be used to help prevent non-alcoholic fatty liver disease.

Wu said the study would not have been possible without the collaboration of the Central Texas Veterans Health Care System and Baylor Scott & White Research Institute's team at the Baylor Scott & White Digestive Disease Research Center.

"Many members of the study team, including Alpini and Francis, as well as Drs. Fanyin Meng and Shannon Glaser, associate professor of medical physiology at Texas A&M College of Medicine, are also affiliated with one or more of these institutions," he said.

Chaodong Wu

Holly Shive

Texas A&M AgriLife Communications

Related Fatty Liver Disease Articles:

Bariatric surgery may be effective treatment for non-alcoholic fatty liver disease
Bariatric surgery may be an effective treatment for non-alcoholic fatty liver disease (NAFLD), suggests a new study accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in the Journal of the Endocrine Society.
MAFLD: A new name and definition brings hope for patients with fatty liver disease
An international consensus panel led by researchers from The Westmead Institute for Medical Research (WIMR) has highlighted the need to redefine Non-Alcoholic Fatty Liver Disease (NAFLD), and to name it Metabolic Associated Fatty Liver Disease (MAFLD).
Possible new treatment strategy for fatty liver disease
Researchers at Karolinska Institutet in Sweden have identified a molecular pathway that when silenced could restore the normal function of immune cells in people with fatty liver disease.
Natural compound in vegetables helps fight fatty liver disease
A new study led by Texas A&M AgriLife Research scientists shows how a natural compound found in cruciferous vegetables can also be used to fight fatty liver disease.
Obesity crisis blamed for a rise in fatty liver disease amongst young adults
One in five young people have fatty liver disease (steatosis), with one in 40 having already developed liver scarring (fibrosis), research published today has found.
Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).
Scientists closer to solving mystery of why lean people get fatty liver disease
Researchers from The Westmead Institute for Medical Research (WIMR) have discovered how fatty liver disease develops in lean people, aiding the development of potential treatments for these patients.
How common is alcoholic fatty liver disease?
This study used national survey data from 2001-2016 to examine how common alcoholic fatty liver disease is in the United States.
Researchers identify a protein that protects against non-alcoholic fatty liver disease
Work headed by scientist Antonio Zorzano proposes a possible therapeutic target to treat fatty liver, a disease for which there is currently no treatment.
A new molecule to fight type 2 diabetes and non-alcoholic fatty liver disease
A new molecule -EPB-53-, could help fight type 2 diabetes and the non-alcoholic fatty liver disease.
More Fatty Liver Disease News and Fatty Liver Disease Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at